Pharma BD Deal Intelligence
A ~$592M bolt-on that Shire itself wrote down twice within three years, with US approval (Motegrity, 2018) arriving only after Shire had been acquired by Takeda. Resolor never hit its original peak-sales case, undercut by a challenging European reimbursement environment and modest US uptake.
Chairman Staf Van Reet: 'This transaction, when completed, will create significant shareholder value. This offer is a further remarkable milestone in Movetis'…
Shire's Mike Cola called Movetis 'a highly complementary fit for our GI business unit'; Shire estimates Resolor peak sales above €300M, citing strong patent…
Movetis was a 2006 J&J spinoff that took Resolor through EU approval in 30 countries and a 2009 IPO before Shire's €428M takeout — a fast specialty-pharma…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Shire to acquire Movetis at €19/share cash, valuing equity at €428M (~$565M). Adds Belgian GI specialist with Resolor. Closed October 2010 with 99.21% shares tendered.
Assessment window: 5yr post-close.
Chronic constipation is a common functional GI disorder marked by infrequent, difficult, or incomplete bowel movements lasting three months or longer. It disproportionately affects women and the elderly and is frequently refractory to laxatives, fiber, and lifestyle measures, driving 2.8 million ambulatory and ER visits annually in the US (2010).
At deal close (2010) the chronic constipation market was bifurcated between OTC laxatives (PEG 3350/MiraLAX, bisacodyl, senna) and a small set of prescription prosecretory agents. The dominant Rx brand was Amitiza (lubiprostone, Sucampo/Takeda), a chloride channel activator approved in 2006 for chronic idiopathic constipation; Linzess (linaclotide, Ironwood/Forest) and plecanatide were still in development. Resolor (prucalopride) brought a differentiated mechanism — selective 5-HT4 receptor agonism — with European approval in 30 countries from October 2009 and a clean cardiovascular profile that earlier 5-HT4s (cisapride, tegaserod) lacked. Shire valued the deal on a peak-sales estimate above €300M and viewed Movetis as a complementary fit to its specialty GI franchise. The acquisition gave Shire an immediately marketed European specialty GI asset, a US development opportunity (later out-licensed to Sucampo in 2012), and a pipeline of additional GI candidates from the J&J/Janssen heritage. The deal materially expanded Shire's specialty GI footprint beyond Pentasa/Lialda.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Movetis NV (this deal) | 2010 | $565M | 37 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
← Browse all deals · How we score deals
More: 2010 deals · Shire plc deals · Gastroenterology deals